专栏名称: 医药代表
本号为正版MRCLUB「医药代表」微信,谨防山寨!——医药行业的那些事儿,新手指导,招聘信息,业内新闻推送,25万药代会员及医药市场销售管理人员每天从我们这获得职业指导及业内动态。
目录
相关文章推荐
医学影像沙龙  ·  手把手教你学X线诊断... ·  2 天前  
蒲公英Ouryao  ·  CDE:两指导原则发布→肽类/抗体类药物 ·  3 天前  
51好读  ›  专栏  ›  医药代表

美国芝加哥7月1日新规,医药代表必须持证上岗

医药代表  · 公众号  · 医学  · 2017-07-23 23:04

正文

芝加哥市长伊曼纽尔在新条例颁布时表示,尽管制药行业对新条例持反对意见,但这一举措得到了市议会的批准,并成为全国最严厉的药品行业管制规定。

来源/芝加哥侨报 魏奕


【侨报记者魏奕7月17日芝加哥报道】据DNAinfo7月16日最新报道,为减少处方阿片类药物(含鸦片类药)被过度滥用的风险,控制成瘾死亡逐年上升的趋势。芝加哥市府颁布新条例严格管理药品行业,医药代表必须“持证上岗”,违规者将接受处罚。


芝加哥严管药品行业,2017年7月1日起新条例规定医药代表必须每年申请许可执照,持证上岗


2017年7月1日生效的新条例规定,医药代表许可证必须每年更新一次,每次申请费均为750美元。违反规定者将面临1000至3000美元的罚款,并被吊销执照至少两年时间。同时,该条例注明,医药代表一年中在芝加哥经营业务时间不足15天者,则无须申请许可证。


芝加哥市政官员指出,阿片药物过度滥用导致不少生命成瘾死亡,案例逐年增加


芝加哥市政官员表示,新条例规定的执照许可证是每年更新并缴费支付,同时医药代表也要接受社会责任道德培训,并向芝加哥居民公示他们的营销现状和药品种类。新条例还要求医药代表记录跟踪向医生和其他医护人员销售药品的信息,以帮助减少药物滥用的风险。芝加哥居民如发现医药代表的违规营销活动,可拨打311进行投诉。


此前在2016年一次预算听证会上,制药行业协会代表强烈反对市府提出医药代表持证上岗的提案,并称这项“昂贵”的措施要求“繁冗低效”,不能阻止阿片类药物滥用的流行。但议案最终通过并在2017年7月1日执行。芝加哥市长伊曼纽尔(Rahm Emanuel)在新条例颁布时表示,尽管制药行业对新条例持反对意见,但这一举措得到了市议会的批准,并成为全国最严厉的药品行业管制规定。


根据市长办公室的一份声明表示,“有证据表明,滥用处方类阿片类药物通常是海洛因成瘾的途径。执法人员报告中也提到,非法海洛因交易也是其他类型犯罪的催化剂。”据库克郡法医办公室的数据显示,2016年芝加哥大约有684例与海洛因有关的死亡病例。数据显示,这一数字比2015年增加了近97%。因此,芝加哥市府颁布条例,通过规定医药代表持证营销,期望改变药物滥用导致成瘾的现状。


芝加哥公共卫生专员朱莉·莫里塔博士(Julie Morita)表示,许可证新条例的颁布令人期待,芝加哥市府加强制药企业责任的管控,为居民创造了新的医药品获取保障,该项举措领先于全国。同时,这一改进将有助于确保医生和居民了解到所需药品的准确信息,减少过度滥用导致上瘾的可能性。


附:医药代表许可证条例草案

by 美国芝加哥市 2017年3月


1. 定义


Definitions for terms used in these Rules can be found in Section 4-6-310 of the Municipal Code of Chicago. The following terms are further defined for the purposes of these Rules.


  • “BACP” means the Chicago Department of Business Affairs and Consumer Protection.

  • “CDPH” means the Chicago Department of Public Health.

  • “Health care professional” shall mean any physician or other health care practitioner who is licensed to provide health care services or to prescribe pharmaceutical or biologic products. However, health care professional shall not be interpreted to include health care practitioners who work exclusively with animals.

  • “Medical Science Liaison” means a person with an advanced science or medical degree who provides technical assistance to healthcare professionals and does not carry out a marketing or sales function. Medical Science Liaisons may also be known by other titles including but not limited to Medical Liaison, Medical Manager, Regional Scientific Manager, Clinical Liaison, and Scientific Affairs Manager.

  • “Ordinance” means Section 4-6-310 of the Municipal Code of Chicago.

  • “Pharmaceutical representative” means a person who markets or promotes pharmaceuticals to health care professionals and excludes Medical Science Liaisons.


2. 许可证要求


Per Section 4-6-310(b) of the Municipal Code of Chicago, a license is required to conduct business as a pharmaceutical representative in the City of Chicago for fifteen or more days per calendar year. A person conducting business as a pharmaceutical representative must show the license or an exact copy thereof when contacting a health care professional in person if the health care professional asks to see it.


As defined in the Code, a “pharmaceutical representative” means a person who markets or promotes pharmaceuticals to health care professionals.


These regulations shall not apply to individuals who provide information about a pharmaceutical product solely for the purpose of clinical trials, investigational drugs, or a Risk Evaluation and Mitigation Strategy pursuant to the Federal Food, Drug and Cosmetic Act.


3. 职业教育要求


In order to satisfy the professional education requirement for an initial pharmaceutical representative license, applicants must complete an online course that will be available at www.cityofchicago.org/health. This course will provide an introduction to the pharmaceutical representative license, an overview of the Ordinance’s ethical standards and disclosure requirements, and other topics appropriate to the license. Proof of completion of the online course must accompany the application for the pharmaceutical representative license.


In order to renew a pharmaceutical representative license, applicants must complete five hours of continuing professional education. By applying for renewal, the applicant is affirming that he has completed five hours of continuing education during the previous year. The continuing education must be provided by an institution approved by CDPH to provide such education. The continuing education coursework must be in one or more of the following subject areas:


1) General medical and pharmaceutical terminology and abbreviations

2) Food and Drug Administration laws and regulations pertaining to drug marketing, labeling, and clinical trials

3) The cost effectiveness of pharmacological treatments

4) Therapeutic drug classes and categories

5) Professional ethics

6) Properties and actions of drugs and drug delivery mechanisms

7) Etiologies, characteristics, and therapeutics of disease states

8) Pharmacology

9) The anatomical and physiological effect of pharmaceuticals

10) The comparative effectiveness of pharmacological treatments

11) How to read and analyze peer-reviewed literature on pharmacological treatments

12) Safe prescribing practices to prevent abuse


CDPH will audit renewal applications to confirm that applicants completed the continuing education requirements. Upon request, applicants must provide information on courses completed, including the title and date of the course(s), number of credit hours completed, name of the education provider(s), and signed certificate(s) of completion. CDPH may confirm this information with the continuing education provider(s). If a licensed pharmaceutical representative’s continuing education requirements have not been met and/or were fraudulently affirmed, the pharmaceutical representative in violation may face suspension or revocation of the license, inclusion in a public list of pharmaceutical representatives whose licenses have been revoked, and a fine of no less than $1,000.00 and no more than $3,000.00 per day of violation.


A list of approved course providers will be posted at www.cityofchicago.org/health. Courses offered by an approved provider satisfy the continuing education requirements as long as the course is primarily focused on one of the approved subjects listed in this Section.


Institutions or organizations seeking to provide continuing education courses in the subjects referenced above can find an application for approval by CDPH at www.cityofchicago.org/health. To qualify for approval, a continuing education program shall be an educational program given at a conference, lecture, seminar, course of instruction, workshop, or on the Internet and must be provided by:


1) a nationally or locally accredited program provider; 2) a governmental unit; 3) a health care facility; or 4) an institution of higher learning recognized by an accrediting body approved by the Secretary of the United States Department of Education. A pharmaceutical company that employs or in any way provides compensation to any pharmaceutical representative shall not be an approved education provider.


Approved education providers must submit course titles, course descriptions, and course curricula to CDPH through the process indicated at www/cityofchicago.org/health.


It is the responsibility of the continuing education provider to provide participants with a certificate of course completion containing the name and address of the provider; the name and address of the participant; the course name; the number of course hours completed; the date and location of the course; and the signature of the provider. Providers and pharmaceutical representatives must maintain records of this information for at least five years.


Each annual renewal will also require review, through the online application process, of the ethical standards set out in Section 5 of these rules.


4. 信息披露


Pharmaceutical representatives shall provide the information required by the Ordinance annually upon the end of each license period. Pharmaceutical representatives shall also provide the information upon request by the Commissioner of Public Health. The information shall be compiled and submitted in a format that will be described on the CDPH website at www.cityofchicago.org/health.


The time periods covered in the information shall be as follows:


A) After a pharmaceutical representative receives his initial license, the information will be due in one year and cover the 11-month time period starting from the day of initial licensure and lasting until one month before license expiration.


B) After a pharmaceutical representative receives a license renewal, the information will cover the 12-month time period starting one month before the license renewal and lasting until one month before license expiration.


If the Commissioner of Public Health requests the information at other times, the information will be due within 30 days of the request and shall cover a time period designated by the Commissioner, provided that the time period ends no later than 30 days before the request was made.


5. 道德标准


Licensed pharmaceutical representatives shall adhere to the following ethical standards:


1) A pharmaceutical representative shall not engage in any deceptive or misleading marketing of a pharmaceutical product, including the knowing concealment, suppression, omission, misleading representation, or misstatement of any material fact.


2) A pharmaceutical representative shall not use a title or designation that could reasonably lead a licensed health professional, or an employee or representative of a licensed health professional, to believe that the pharmaceutical representative is licensed to practice medicine, nursing, dentistry, optometry, pharmacy, or any other similar health occupation, unless the pharmaceutical representative holds an active license to practice that health occupation.


3) A pharmaceutical representative shall not attend patient examinations or have any direct contact with patients without the express, written consent of the patient. The representatives also shall not enter an area meant primarily for healthcare providers and patients, other than a designated waiting area, unless invited in by a healthcare provider working on site.


4) A pharmaceutical representative shall not harass, intimidate, or coerce a licensed health professional, or an employee or representative of a licensed health professional, through any form of communication, including expressing disappointment for the failure to prescribe certain medications.


5) A pharmaceutical representative shall cease making sales calls to a health professional, or an employee or representative of a health professional, if the health professional requests it in writing or verbally to the pharmaceutical representative or the representative’s employer.


6) A pharmaceutical representative shall not make any misleading statements to gain access to a healthcare professional.


7) A pharmaceutical representative shall provide healthcare professionals with information that is accurate and compliant with FDA-approved labeling.


8) A pharmaceutical representative shall comply with the standards of ethical and professional conduct established by the Pharmaceutical Research and Manufacturers of America (PhRMA) in its publication entitled “PhRMA Code on Interactions with Healthcare Professionals” as it may be amended or republished from time to time. Where there is a conflict between the PhRMA publication, the Ordinance and/or these Rules, the Ordinance and the Rules shall control.


6. 投诉


If a health care professional or patient wishes to file a complaint about a pharmaceutical representative for failure to comply with any of the requirements detailed in the Ordinance or these Rules, he may call 311 or submit a complaint through the 311 online complaint system. The complaint shall include the name of the pharmaceutical representative, if known; the pharmaceutical company being represented, if known; the nature of the violation; the date, approximate time, and location of the violation; and any other pertinent information to support the complaint. 


The City will review all complaints and, when warranted, investigate them. Pharmaceutical representatives who violate the Ordinance or these Rules are subject to suspension or revocation of the license and/or a fine of no less than $1,000 and no more than $3,000 per day of violation. (医药代表微信号:mrclub)


MRCLUB原创作者招募中

数十万精准会员每日阅读,助您快速提升个人品牌,扩大在医药行业及社会化媒体的影响力!(详情请访问网站http://wemr.club)

医药代表 伴您成长!